ScripThe past year has seen an increase in investment in biopharma companies following a couple of lean years, but the sector is not fully out of the woods yet. However, most industry leaders see funding
In VivoCommercializing cell and gene therapies is a major problem for manufacturers, even if their products have proven successful in clinical studies. For companies whose therapies do make it to the market,